

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 July 2014 (24.07.2014)



(10) International Publication Number
WO 2014/110705 A9

(51) International Patent Classification:

C07D 498/04 (2006.01) **A61K 31/5365** (2006.01)

C07D 409/14 (2006.01) **A61P 31/14** (2006.01)

(21) International Application Number:

PCT/CN2013/001676

(22) International Filing Date:

31 December 2013 (31.12.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2013/000038

16 January 2013 (16.01.2013)

CN

(71) Applicant: **MERCK SHARP & DOHME CORP.**

[US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(72) Inventors; and

(71) **Applicants (for US only):** **YU, Wensheng** [CN/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **TONG, Ling** [CN/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **KOZLOWSKI, Joseph A.** [US/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **SELYUTIN, Oleg** [US/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **CHEN, Lei** [CN/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **KIM, Jae-Hun** [KR/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **SHA, Deyou** [US/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **RIZVI, Razia** [US/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **SHANKAR, Bandarpalle** [US/US]; Merck Research Laboratories, 126 E. Lincoln Avenue, Rahway, New Jersey 07065 (US). **HU, Bin** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **ZHONG, Bin** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade

Zone, Shanghai 200131 (CN). **WAI, Dahai** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **HAO, Jinglai** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **WEI, Wei** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **JL, Tao** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN). **ZAN, Shuai** [CN/CN]; Wu Xi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131 (CN).

(74) **Agent:** **LIU, SHEN & ASSOCIATES**; 10th Floor, Building 1, 10 Caihefang Road, Haidian District, Beijing 100080 (CN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:


— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

5 March 2015

[Continued on next page]

(54) **Title:** HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES



(57) **Abstract:** The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A', R², R³, R⁴ and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

- (15) Information about Correction:**
see Notice of 5 March 2015